These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812 [TBL] [Abstract][Full Text] [Related]
43. Psychedelic drugs: the ups and downs of ecstasy. Check E Nature; 2004 May; 429(6988):126-8. PubMed ID: 15141183 [No Abstract] [Full Text] [Related]
44. The Past and Future of Psychedelic Science: An Introduction to This Issue. Doblin RE; Christiansen M; Jerome L; Burge B J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970 [TBL] [Abstract][Full Text] [Related]
45. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Jones GM; Nock MK J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261 [TBL] [Abstract][Full Text] [Related]
46. Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. Raut SB; Marathe PA; van Eijk L; Eri R; Ravindran M; Benedek DM; Ursano RJ; Canales JJ; Johnson LR Pharmacol Ther; 2022 Nov; 239():108195. PubMed ID: 35489438 [TBL] [Abstract][Full Text] [Related]
47. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Barnett BS; Greer GR J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406 [TBL] [Abstract][Full Text] [Related]
52. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683 [TBL] [Abstract][Full Text] [Related]
53. The therapeutic potential of psilocybin: a systematic review. van Amsterdam J; van den Brink W Expert Opin Drug Saf; 2022 Jun; 21(6):833-840. PubMed ID: 35225143 [TBL] [Abstract][Full Text] [Related]
54. The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. Sessa B Psychopharmacology (Berl); 2018 Feb; 235(2):551-560. PubMed ID: 28831571 [TBL] [Abstract][Full Text] [Related]
55. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. Marseille E; Kahn JG; Yazar-Klosinski B; Doblin R PLoS One; 2020; 15(10):e0239997. PubMed ID: 33052965 [TBL] [Abstract][Full Text] [Related]
57. Policy in focus: Is psilocybin the next cannabis? Basky G CMAJ; 2021 Nov; 193(45):E1741-E1742. PubMed ID: 34782381 [No Abstract] [Full Text] [Related]
58. Psychedelic science in post-COVID-19 psychiatry. Kelly JR; Crockett MT; Alexander L; Haran M; Baker A; Burke L; Brennan C; O'Keane V Ir J Psychol Med; 2021 Jun; 38(2):93-98. PubMed ID: 32811575 [TBL] [Abstract][Full Text] [Related]
59. Psilocybin for treating substance use disorders? de Veen BT; Schellekens AF; Verheij MM; Homberg JR Expert Rev Neurother; 2017 Feb; 17(2):203-212. PubMed ID: 27684102 [TBL] [Abstract][Full Text] [Related]
60. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis. Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]